
AdvaMed® Advancements: Q1 2025 Report
AdvaMed’s Q1 2025 report focuses on tariffs, policy action, and how we’re protecting Medtech innovation.
Stay up to date on tariff policies that impact your global operations. This section provides insights on trade developments, regulatory changes, and AdvaMed’s advocacy to minimize tariff burdens on medtech manufacturers and maintain global supply chain stability.

AdvaMed’s Q1 2025 report focuses on tariffs, policy action, and how we’re protecting Medtech innovation.
WASHINGTON – Today AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:

Details a sweeping tariff hike to 84% on Chinese imports and de minimis increases, aiming to protect U.S. economic and national security.
Washington, D.C.– AdvaMed®, the Medtech Association, and nine additional organizations urged an exemption from tariffs for medical and dental supplies, equipment, and devices, citing concerns about increased costs resulting in supply…
Washington, D.C.– AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker: “Our country is the birthplace of the medical device and technology industry and leads the…

Tariffs on medical goods threaten healthcare costs, access, and supply chains. Leading health groups urge exemptions to safeguard patient care.

Tariffs on medtech could disrupt supply chains, increase costs, and delay care. Exemptions are needed to protect hospitals, patients, and innovation.

A breakdown of the administration’s trade policy, highlighting key areas where the U.S. seeks to level the playing field with trading partners through reciprocal tariffs.

A policy memorandum outlining the administration’s strategy for fair and reciprocal trade, addressing tariff imbalances and protecting American industries.

Essential advocacy insights on how new tariffs impact the MedTech industry. Use these key messages when engaging with policymakers, industry stakeholders, and media.